Prognostic significance of flow cytometric immunophenotyping in acute myeloid leukemia.
The prognostic significance of flow cytometric immunophenotyping (FCI) in acute myeloid leukemia (AML) has been controversial. In this study, we re-investigated the possible role of FCI in the prediction of AML relapse following standard chemotherapy. A total of 209 AML cases with follow-up information were analyzed. Among those, 78 cases were in remission (M:F=44/34; mean age of 48.9 years) and 131 had relapse (M:F=71/60; mean age of 51.3 years). The expression of CD34, HLA-DR or a combination of both was significantly different between the remission and relapse groups for all AML as well as AML without t(15;17). None of the pammyeloid markers or their combinations analyzed was found to correlate with treatment outcomes. Complex cytogenetic abnormalities were more likely associated with relapse group than with remission group, but were not statistically significant after excluding AML with t(15;17). In conclusion, FCI is useful in predicting treatment outcome and disease relapse in AML.
Webber
Brian A
BA
Department of Pathology and Laboratory Medicine, Emory University School of Medicine Atlanta, GA, USA.
Cushing
Melissa M
MM
Li
Shiyong
S
Leukemia. 2006 May;20(5):888-91
16525493
Blood. 1991 May 15;77(10):2242-50
1709379
Leukemia. 1992 May;6(5):393-9
1375696
Leuk Res. 1994 Jan;18(1):29-35
8289464
Am J Clin Pathol. 2002 Oct;118(4):560-6
12375643
Haematologica. 2004 May;89(5):528-40
15136215
Leuk Res. 2005 Oct;29(10):1109-16
16095690
Am J Clin Pathol. 1998 Feb;109(2):211-20
9583894
Leuk Res. 2007 Jan;31(1):113-6
16730795
Ann Hematol. 2007 May;86(5):311-27
17375301
J Cancer Res Clin Oncol. 1994;120(9):553-7
8045921
Leukemia. 1994 Mar;8(3):388-94
7907393
Leuk Lymphoma. 1995 Mar;17(1-2):111-9
7539657
Cancer Res. 2001 Jun 1;61(11):4483-9
11389079
J Clin Oncol. 1990 Mar;8(3):423-30
2307987
Am J Clin Pathol. 2000 Feb;113(2):193-200
10664621
Haematologica. 2002 Nov;87(11):1135-40
12414342
Blood. 1995 Apr 15;85(8):2147-53
7536492
Arch Pathol Lab Med. 2003 Jan;127(1):42-8
12521365
Leukemia. 1998 Jul;12(7):1056-63
9665190
Leukemia. 1992 Nov;6(11):1203-9
1279324
Hematol Oncol. 1990 Jan-Feb;8(1):47-58
2404842
Am J Hematol. 2006 Apr;81(4):227-35
16550517
Leuk Res. 2004 Jan;28(1):43-8
14630079
Br J Haematol. 1989 Jun;72(2):161-6
2757962
Blood. 1995 Oct 15;86(8):3097-108
7579404
Leukemia. 1994 May;8(5):823-6
7514247
Blood. 1998 Oct 1;92(7):2322-33
9746770
Baillieres Clin Haematol. 1996 Mar;9(1):87-105
8730552
Cancer. 2006 Feb 15;106(4):839-47
16419072
Leukemia. 1997 Nov;11(11):1878-86
9369421
Am J Clin Pathol. 1992 Oct;98(4):430-6
1415023
Leuk Res. 1997 Oct;21(10):985-95
9403009
Am J Hematol. 1998 Aug;58(4):278-84
9692390
Leukemia. 2007 Jun;21(6):1204-11
17410192
Blood. 2000 Aug 1;96(3):870-7
10910899
Neoplasma. 2005;52(5):402-10
16151585
Blood. 1994 Aug 15;84(4):1220-5
8049437
Leuk Res. 1997 Jul;21(7):603-7
9301680
Haematologica. 2001 Aug;86(8):801-6
11522535
Blood. 1998 May 1;91(9):3401-13
9558399
Haematologica. 1993 May-Jun;78(3):151-5
7690733
Neoplasma. 2006;53(2):155-60
16575472
Leukemia. 2003 Apr;17(4):707-15
12682628
Semin Hematol. 2001 Apr;38(2):124-38
11309694
Blood. 1997 Aug 15;90(4):1643-8
9269784
Am J Hematol. 2001 Oct;68(2):69-74
11559944
Blood. 1993 May 1;81(9):2399-405
7683218
Leuk Lymphoma. 1994;13 Suppl 1:81-5
7521238